Medicare Part D

CMS backs off Part D revision

The agency's move to limit the formulary for certain drug classes is dead.

Proposed budget gets mixed reviews

The White House's proposed FY 2015 budget gives an additional 1% to the FDA.

Antidepressants may have to fight for Part D coverage

CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.

Study shows how brand Rx drain Medicare

ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.

J&J painkiller probe expands scrutiny of industry marketing

By

HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.

Actavis gets go-ahead to expand generic painkiller portfolio

By

The drug maker can now add five new doses to its generic Opana ER offerings.

CBO: more scripts filled, less healthcare spending

By

The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.

Voting with their wallets, pharmas say no thanks to change

Voting with their wallets, pharmas say no thanks to change

By

Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?

In PhRMA-White House emails, little sizzle, less scandal

In PhRMA-White House emails, little sizzle, less scandal

By

Congressional Republicans are trumpeting a cache of emails that give a glimpse into how the White House's deal with the pharma industry on healthcare reform came together. There's not much 'there' there, but there are some titillating glimpses into the legislative sausage factory.

Co-pay cards and coupons sway 2 million US seniors, study says

Co-pay cards and coupons sway 2 million US seniors, study says

By

The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.

President's budget would deal a wallop to biopharma wallets

President's budget would deal a wallop to biopharma wallets

By

President Obama's proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade - discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.

Aging Committee raps pharma on brand drug price hikes

Aging Committee raps pharma on brand drug price hikes

By

Armed with AARP and Kaiser Family research, members of the Senate Special Committee on Aging asked panelists why brand drug prices in the US continue to increase, while other countries pay half as much for the same products.

PhRMA pledges $80B toward drug savings

By

PhRMA has committed to finding $80 billion in savings on drugs sold in the US over 10 years, including selling drugs at half-price to seniors in the Medicare Part D "donut hole" coverage gap.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.